Evidence map›Paper›PMID 32690918›Full record

ReviewNature reviews. Endocrinology2020

Diet and exercise in the prevention and treatment of type 2 diabetes mellitus.

Faidon Magkos, Mads F Hjorth, Arne Astrup

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06759922 (Clinical Efficacy and Safety of Glimepiride, Empagliflozin and Sitagliptin With Metformin in Type 2 Diabetes Mellitus), which is not on this map. Cited by 238 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
238citing papers in PubMed, 9 pooled it
27.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06759922 phase4completedstarted 2025, after this paper: background citation

Clinical Efficacy and Safety of Glimepiride, Empagliflozin and Sitagliptin With Metformin in Type 2 Diabetes Mellitus: A Double and Triple Drug Therapy

Ran2025Enrolled172Registered outcomes2Posted comparisons0ConditionsType 2 Diabetes MellitusArmsTab Metformin + Tab Empagliflozin, Tab Metformin + Tab Empagliflozin + Tab Sitagliptin, Tab Metformin + Tab Glimepiride, Tab Metformin +Tab Sitagliptin
PMID 34388848PMID 31081587PMID 30961501PMID 32041141PMID 33736819PMID 34352984PMID 34385345PMID 35309368PMID 35668219PMID 36151309PMID 36507650PMID 37809225other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

238 citing papers in PubMed, 9 syntheses or guidelines pooled it, 460 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Enhancing Motivation to Reduce Restrictive Eating: A Novel Approach.The International journal of eating disorders · 2025
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Review

178 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Faidon MagkosDepartment of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Frederiksberg Campus, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-1312-7364
Mads F HjorthDepartment of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Frederiksberg Campus, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-9440-2737
Arne AstrupDepartment of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Frederiksberg Campus, Copenhagen, Denmark. ast@nexs.ku.dk.ORCID http://orcid.org/0000-0001-8968-8996
University of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evidence from observational studies and randomized trials suggests that prediabetes and type 2 diabetes mellitus (T2DM) can develop in genetically susceptible individuals in parallel with weight (that is, fat) gain. Accordingly, studies show that weight loss can produce remission of T2DM in a dose-dependent manner. A weight loss of ~15 kg, achieved by calorie restriction as part of an intensive management programme, can lead to remission of T2DM in ~80% of patients with obesity and T2DM. However, long-term weight loss maintenance is challenging. Obesity and T2DM are associated with diminished glucose uptake in the brain that impairs the satiating effect of dietary carbohydrate; therefore, carbohydrate restriction might help maintain weight loss and maximize metabolic benefits. Likewise, increases in physical activity and fitness are an important contributor to T2DM remission when combined with calorie restriction and weight loss. Preliminary studies suggest that a precision dietary management approach that uses pretreatment glycaemic status to stratify patients can help optimize dietary recommendations with respect to carbohydrate, fat and dietary fibre. This approach might lead to improved weight loss maintenance and glycaemic control. Future research should focus on better understanding the individual response to dietary treatment and translating these findings into clinical practice.

Indexed as

Diet TherapyExercise TherapyCaloric RestrictionDiabetes Mellitus, Type 2HumansObesityPrediabetic StateTreatment OutcomeWeight Loss

Identifiers

PMID32690918
OpenAlexW3043249795

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.